Dec 9, 2020
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of
Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's
Disease and more.
https://www.abivax.com/pipeline/
- #COVID-19
https://www.abivax.com/pipeline/abx464-for-covid-19/
Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial),
the unique properties of the lead candidate (antiviral,
anti-inflammatory, tissue repair) to treat elderly and high-risk
Covid-19 patients, the rial is ongoing in Europe and Brazil
(Mexico, Peru and Chile to follow shortly)
-#Cancer
https://www.abivax.com/pipeline/abx196/
ABX196 has been developed as a synthetic agonist of iNKT cells from
a proprietary platform technology that identifies agonists of these
types of cells that demonstrate immune enhancing effects in cancer
models.
Preclinical data showed that ABX196 enhanced anti-tumoral activity
when used alone and in combination with anti-PD1 antibodies or
doxorubicin.
- Ulcerative Colitis
https://www.abivax.com/pipeline/abx464-ibd-uc/
ABX464 in Inflammatory Bowel Diseases (Abivax development
priority), excellent two-year efficacy and safety data for ABX464
ulcerative colitis Phase 2a maintenance study and ongoing
ulcerative colitis Phase 2b trial in 15 countries, the US and
Canada
- Crohn’s disease
https://www.abivax.com/pipeline/abx464-for-crohns-disease/
Planned pivotal Phase 2b/3 trial with ABX464 in Crohn’s disease
(FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid
arthritis in 5 European countries
- HC
Ongoing clinical trial with second molecule, ABX196, in patients
with hepatocellular carcinoma in the US